Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bayer Said to Be in Exclusive Talks for Merck OTC Unit

Don't Miss Out —
Follow us on:
Merck & Co. Inc. Office In Shanghai
A man walks through a Merck & Co. Inc. office in Shanghai. Merck shares rose 1.8 percent to $59.62 at the close in New York, their highest level since January 2008. Photographer: Kevin Lee/Bloomberg

May 2 (Bloomberg) -- Bayer AG is in exclusive talks to acquire Merck & Co.’s consumer business and is prepared to pay about $14 billion for the division, people with knowledge of the matter said.

An announcement is likely to come in the next few days, said the people, who asked not to be identified because the talks are private. While the two sides have agreed to a deal in principle, they are still working out details and haven’t formally reached an agreement, the people said. The terms would include cash and an exchange of pharmaceutical assets, possibly structured as a joint venture, the people said.

A deal would strengthen Merck’s core drug business while helping Bayer to beef up its consumer-products line by adding brands including Claritin allergy relief. It would be similar to other recent pharmaceutical transactions, in which companies have sold weaker business lines and added to areas where they are more competitive.

Companies including Reckitt Benckiser Plc, Procter & Gamble Co. and Sanofi had made bids for Merck’s over-the-counter business. Reckitt said it was withdrawing from talks because the unit had become too expensive. Still, if Bayer and Merck don’t complete a deal, previous bidders and other potential suitors could reconsider the asset.

Steve Cragle, a spokesman for Merck, said in a phone interview he had no comment. Guenter Forneck, a spokesman for Bayer, also declined to comment.

Pharma Moves

Bayer rose 0.4 percent to 100.40 euros at 10:49 a.m. in German trading. Sanofi rose 0.5 percent to 78.41 euros in Paris, while Reckitt Benckiser fell 0.7 percent to 4,849 pence in London. Procter & Gamble closed down 0.3 percent to $82.34 yesterday in New York, while Merck closed up 1.8 percent at $59.62.

When Merck, based in Whitehouse, New Jersey, first put the maker of Claritin allergy medicine and Coppertone sunblock up for sale, people familiar with the matter expected it to fetch about $10 billion.

Other companies are reworking their businesses as well. In April, GlaxoSmithKline Plc sold its oncology portfolio to Novartis AG for $14.5 billion. Novartis sold Glaxo its vaccines business for $5.25 billion and sold its animal-health unit to Eli Lilly & Co. for $5.4 billion.

Merck shares rose 1.8 percent to $59.62 at the close in New York yesterday, their highest level since January 2008. Bayer, based in Leverkusen, Germany, didn’t trade yesterday because of a holiday in Europe. The company’s U.S. American depositary shares gained less than 1 percent to $139.66.

Bayer’s over-the-counter portfolio is anchored by the iconic pain pill aspirin. It is the third-biggest company in over-the-counter drugs by sales, behind Johnson & Johnson and Glaxo, according to a ranking compiled by Glaxo for the announcement of its deal with Novartis.

To contact the reporter on this story: David Welch in New York at

To contact the editors responsible for this story: Mohammed Hadi at Elizabeth Wollman, Bruce Rule

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.